Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis
Open Access
- 1 January 2011
- journal article
- Published by Hindawi Limited in Neurology Research International
- Vol. 2011, 1-6
- https://doi.org/10.1155/2011/256460
Abstract
The induction of immunologic tolerance is an important clinical goal in autoimmunity. CD4+regulatory T (Treg) cells, defined by the expression of the transcription factor forkhead box P3 (FoxP3), play a central role in the control of autoimmune responses. Quantitative and qualitative defects of Tregs have been postulated to contribute to failed immune regulation in multiple sclerosis (MS) and other autoimmune diseases. This paper highlights the potential uses of T regulatory cell epitopes (Tregitopes), natural Treg epitopes found to be contained in human immunoglobulins, as immunomodulating agents in MS. Tregitopes expand Treg cells and induce “adaptive Tregs” resulting in immunosuppression and, therefore, are being considered as a potential therapy for autoimmune diseases. We will compare Tregitopes versus intravenous immunoglobulin (IVIg) in the treatment of EAE with emphasis on the potential applications of Tregitope for the treatment of MS.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R43DK081261)
This publication has 51 references indexed in Scilit:
- Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4+ T cells against the swine-origin H1N1 influenza virusVaccine, 2011
- Prevention of type 1 diabetes: today and tomorrowDiabetes/Metabolism Research and Reviews, 2010
- IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cellsThe Journal of Experimental Medicine, 2010
- Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor–specified peripheral niche constraintsThe Journal of Experimental Medicine, 2010
- Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeuticsClinical Immunology, 2009
- Identification of a receptor required for the anti-inflammatory activity of IVIGProceedings of the National Academy of Sciences of the United States of America, 2008
- Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”Blood, 2008
- Interleukin-17 Production in Central Nervous System-Infiltrating T Cells and Glial Cells Is Associated with Active Disease in Multiple SclerosisThe American Journal of Pathology, 2008
- Molecular analysis of expression and function of hFcγRIIbl and b2 isoforms in myeloid cellsMolecular Immunology, 2006
- IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patientsAutoimmunity, 2005